Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates
Executive Summary
The Swiss firm that discovered Biogen’s Alzheimer’s therapy aducanumab has built a pipeline of clinical programs across neurological and other diseases and may seek additional partners as candidates advance.
You may also be interested in...
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Biogen’s Q2 Highlights Need For Near-Term Successes
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
A Runaway Hit In US, Pfizer Gains EU Nod for Vyndaqel In Cardiomyopathy
Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.